Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpectra (di/ S) Regulatory News (SPSC)

Share Price Information for Spectra (di/ S) (SPSC)

Share Price is delayed by 15 minutes
Get Live Data
160.00    0.00 (0.00%)
Bid:
120.00
Ask:
200.00
Spread: 80.00 (66.667%)
Market Cap: £77.39m
SPSC Live PriceLast checked at - London Stock Exchange

Intraday Spectra (di/ S) Share Chart

Exercise of Options

9 Jan 2025 07:00

RNS Number : 6585S
Spectra Systems Corporation
09 January 2025
 

Spectra Systems Corporation

(the "Company")

Exercise of Options

Spectra Systems Corporation, a leader in machine-readable high speed banknote authentication, brand protection technologies, and gaming security software, announces the exercise of options by an employee of Spectra.

The employee has exercised options over 20,000 shares of common stock of $0.01 each in the Company ("Shares") with an exercise price of US$ 1.54 per share on 7 January 2025. The employee has elected to utilize the net cashless exercise feature and has therefore surrendered 7,996 shares to the Company. Accordingly, the employee will be issued 12,004 shares.

The shares being issued are restricted securities as defined in Rule 144 of the US Securities Act of 1933 and have been issued pursuant to an exemption from registration under Rule 701 promulgated under the US Securities Act of 1933.

Accordingly, the Company has issued and will apply for 12,004 Shares to be admitted to trading on AIM, which is expected to take place on or around 14 January 2025 ("Admission").The Company's issued share capital now comprises:

583,384 shares in the Regulation S stock line ISIN number USU8457D1091 (AIM:SPSC); and

47,669,592 shares in the unrestricted line ISIN number US84756T1060 (AIM:SPSY).

Spectra Systems has no Shares in treasury, therefore 48,252,976 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Enquiries:

 

 

Spectra Systems Corporation

Dr. Nabil Lawandy, Chief Executive Officer

Tel: +1 (0)401 274 4700

 

Zeus (Nominated Adviser and Broker)

Chris Fielding (Director, Investment Banking)

James Bavister (Assistant Director)

Andrew de Andrade (Associate, Corporate Finance) 

 

Allenby Capital Limited (Joint Broker)

Nick Naylor/James Reeve (Corporate Finance)

Amrit Nahal (Sales and Corporate Broking) 

Tel: +44 (0)20 3829 5000

 

 

 

Tel: +44 (0)20 3328 5665

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEFLFETLLITIIE
Date   Source Headline
21st Mar 202311:44 amRNSDividend Record Date
20th Mar 20237:00 amRNSAudited results for year ended 31 December 2022
16th Mar 20234:35 pmRNSExercise of Options
6th Mar 202310:39 amRNSRemoval of Reg S restrictions from common stock
11th Oct 20226:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20227:00 amRNSContract Amendment to a Central Bank
21st Sep 20227:00 amRNSExercise of Options
12th Sep 20227:05 amRNSAppointment of Non-Executive Director
12th Sep 20227:00 amRNSInterim Results for Six Months Ended 30 June 2022
16th Aug 20227:00 amRNSFirst Banknote Disinfection System Sold
15th Aug 20227:00 amRNSNew Central Bank Contract Amendment
28th Jul 20227:00 amRNSShare Buy-Back
1st Jul 20222:31 pmRNSShare Buy-Back
28th Jun 20227:00 amRNSShare Buy-Back
15th Jun 20227:00 amRNSAdditional Central Bank Development Revenues
14th Jun 20227:00 amRNSAppointment of Chief Financial Officer
13th Jun 20227:00 amRNSAnnual General Meeting Update
25th May 20227:00 amRNSExercise of Options and Director/PDMR Shareholding
20th May 20228:44 amRNSRemoval of Regulation S restrictions from shares
20th May 20228:41 amRNSResignation of Chief Financial Officer
3rd May 20227:00 amRNSPosting of Annual Report & Notice of AGM
6th Apr 20221:36 pmRNSRemoval of Reg S restrictions from common stock
28th Mar 20227:00 amRNSGrant of Share Options
21st Mar 20227:00 amRNSResults twelve months ended 31 December 2021
24th Jan 20227:00 amRNSNew contract awards
21st Jan 20227:00 amRNSExercise of Options
6th Dec 20217:00 amRNSNew K-cup Orders in Q4 Exceed Expectations
2nd Nov 20213:37 pmRNSExercise of Options
25th Oct 20214:18 pmRNSRemoval of Regulation S restrictions
11th Oct 20217:00 amRNSLarge Central Bank Order
13th Sep 202110:27 amRNSHolding(s) in Company
25th Aug 202111:23 amRNSRemoval of Regulation S restrictions
21st Jul 20217:00 amRNSBanknote cleaning system also deactivates Covid-19
14th Jun 20217:00 amRNSAnnual General Meeting Update
17th May 20215:12 pmRNSShare Buy-Back
7th May 20214:49 pmRNSShare Buy-Back
6th May 20212:58 pmRNSShare Buy-Back
4th May 20215:51 pmRNSPosting of Annual Report and Accounts, AGM Notice
26th Apr 20211:45 pmRNSExercise of Options
22nd Apr 20217:00 amRNSNew Lottery Contracts
21st Apr 20217:00 amRNSEnhanced sensor capability contract
19th Apr 20211:46 pmRNSExercise of Options
8th Apr 20217:00 amRNSAllowance of Banknote Disinfection Patent
1st Apr 20213:29 pmRNSExercise of Options and Director/PDMR Shareholding
22nd Mar 20217:35 amRNSAudited Results for the 12 months ended 31 Dec 20
10th Feb 20217:00 amRNSExercise of Options
9th Feb 20212:11 pmRNSAppointment of Director
2nd Feb 20217:00 amRNSSecond phase of contract for sensor development
1st Feb 20213:33 pmRNSExercise of Options
20th Jan 20217:00 amRNSExercise of Options and Director/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.